Microbial β-glucuronidase is associated with variations in clozapine serum levels in patients with treatment-resistant schizophrenia
Year: 2026
Type: article
Abstract: Background: Clozapine is the most effective treatment for people with treatment-resistant schizophrenia (TRS). However, clozapine blood levels vary up to 15-fold across patients, and known determinants (cytochrome P450 modulation, smoking, demographics) explain only part of this variability. Identifying additional factors could help lower toxicity risk, reduce reliance on intensive therapeutic drug monitoring, and widen access to an effective treatment. We evaluated whether gut microbial β-glucuronidase was associated with clozapine serum concentration-to-dose (C/D) ratio, hypothesising that intestinal bacterial deconjugation of N-glucuronidated clozapine enables its re-absorption through the enterohepatic circulation. Methods: We conducted a secondary analysis of a cross-sectional cohort of adults with TRS on stable clozapine treatment who provided paired blood and stool samples ( N = 46). Shotgun metagenomic data were processed to quantify microbial β-glucuronidase (KEGG ortholog K01195). Ordinary least squares regression tested the association between β-glucuronidase abundance and clozapine C/D ratio, unadjusted and adjusted for sex, smoking, ethnicity, stool type, constipation, diet, body mass index, age, total antipsychotic dose, and blood-to-stool sample interval. Results: Microbial β-glucuronidase was positively associated with clozapine C/D ratio in the unadjusted model (β = 0.145, 95% CI [0.001, 0.288]; p = 0.048, adjusted R 2 = 0.07). This association strengthened after adjustment (β = 0.236, 95% CI [0.084, 0.388], p = 0.004, adjusted R 2 = 0.25, full covariate model), corresponding to a 26.65% higher C/D ratio per unit increase. β-glucuronidase was not associated with gastrointestinal symptoms (p = 0.235, unadjusted). Conclusions: These findings provide the first evidence that a specific gut microbial enzyme can modulate clozapine exposure in patients. If confirmed in independent cohorts, these findings can pave the way for microbiome-based precision dosing in psychiatry.
Source: Journal of Psychopharmacology
Institutions: The University of Queensland, Queensland Centre for Mental Health Research, Mater Research, Princess Alexandra Hospital, Metro South Health, Addiction and Mental Health Services - MSH, Oxford Health NHS Foundation Trust, National Institute for Health and Care Research, University of Oxford
Language: English
Subfield: Pharmacology
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $4,400
OpenAlex ID: W7236823385
